← All trials
NCT04475601
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 15, 2020
- Primary completion
- Jul 8, 2021
- Completion date
- May 8, 2022
- First posted
- Jul 17, 2020
- Last posted
- Jul 17, 2020
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Norrlands UniversityLead sponsor
- Uppsala UniversityCollaborator
- University of GothenburgCollaborator
- AstellasCollaborator
- Norrlands UniversityCollaborator
- Lund UniversityCollaborator
- Umea UniversityCollaborator
- Västerbotten County CouncilSponsor investigator
- University of UlmCollaborator
- Helsingborgs HospitalCollaborator
- Jonkoping County HospitalCollaborator
- Norrlands UniversityOverall official - principal investigator
- Sundsvall HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.